Medtronic Ups 2027 Forecasts Amid Heart Device Boom

Medtronic has revised its fiscal 2027 forecasts upward, driven by robust demand for heart devices utilized in complex cardiovascular procedures. The company increased its projected annual organic revenue growth to a range of 7.25% to 7.75%, compared to the previous 6.75% to 7.25%. Additionally, the lower end of its adjusted per share profit forecast was raised to $5.94 from $5.90, with the upper limit remaining at $6.

Strategic Investments and Market Expansion

In a bid to strengthen its market position, Medtronic announced an $80 million investment in Pi-Cardia, a heart-valve repair device maker, with an option to acquire it for $210 million. The company also invested $700 million in Cornerstone Robotics, securing distribution rights for a robotic surgical device in select markets outside the United States. This move aligns with CEO Geoff Martha's strategy to focus on high-growth segments with substantial patient pools.

During a call with investors, Martha highlighted the increasing contributions from newer growth platforms and the company's strategic focus. He noted that the penetration of soft tissue robotic surgery in emerging markets remains below 1%, indicating significant potential for growth, particularly with Cornerstone's Sentire device complementing Medtronic’s existing Hugo platform.

Strong Cardiovascular Segment Performance

Medtronic's cardiovascular segment reported a 19.5% increase in quarterly sales, reaching $3.93 billion. This growth was largely fueled by the pulsed field ablation portfolio, which targets irregular heart rhythms and achieved an impressive 88% growth rate. The company reported an adjusted quarterly per share profit of $1.45 on revenue of $9.76 billion, surpassing analyst expectations of $1.39 per share on $9.55 billion in sales, according to data compiled by LSEG.

Medtronic's Chief Financial Officer, Thierry Pieton, mentioned that recent tariff refunds nearly offset the duties paid during the quarter. However, future refunds have not been factored into the financial outlook. As Medtronic continues to leverage its strategic investments and capitalize on the growing demand for heart devices, the company remains optimistic about its financial trajectory.